PhosphoGam expands γδ T cells using proprietary synthetic phosphoantigens, delivering stronger cell fitness, potency, manufacturability, and economics than zoledronate.

​

While both agents activate γδ T cells, zoledronate does so through a stressful, indirect mechanism; PhosphoGam activates them directly and predictably while preserving cell fitness.

​

Zoledronate inhibits FPPS in the mevalonate pathway, forcing IPP accumulation before expansion. This narrow manufacturing window can drive stress, exhaustion, activation-induced cell death, and batch variability.

​

PhosphoGam synthetic phosphoantigens act directly, eliminating the enzymatic intermediary and enabling cleaner, more controllable, high-scale manufacturing.

​

This is a mechanistic reimagining of γδ T-cell immunotherapy—not an incremental improvement.

​

Zoledronate’s core limitation is that expansion can damage the γδ T cells it aims to produce. A 2025 article in the journal Immunology reported that, “despite inducing excessive proliferation of Vδ2 T cells, zoledronate impaired their effector function and caused the upregulation of the inhibitory receptor TIM3.”

​

If you are using zolendronate to expand γδ T cells, there is a good chance that your cells are impaired, your CAR-T transfection is is low, and your manufacturing is highly variable, expensive, and draining technical resources.

 

Independent comparisons show PhosphoGam outperforming zoledronate in fold expansion, purity, fitness, consistency, and potency.

​

PhosphoGam consistently generates billions of cells from small donor samples, with >95% purity, >95% viability, and 2,000x fold expansion. PhosphoGam’s simple, capital-lite protocol can produce hundreds of 1B-cell doses per run at a fraction of the per-dose cost of zoledronate manufacturing or conventional autologous CAR-T.

​